Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356980 · ClinicalTrials.gov registry record · Phase 1
TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00356980 is a Phase 1 study that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 60 participants.
The verdict
NCT00356980, a Phase 1 study, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
RATIONALE: Biological therapies, such as TNF-bound colloidal gold, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of TNF-bound colloidal gold in treating patients with advanced solid tumors.
Interventions
- OTHER pharmacological study
- BIOLOGICAL colloidal gold-bound tumor necrosis factor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00356980
The ClinicalTrials.gov registry entry for NCT00356980 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institutes of Health Clinical Center (CC), which has 338 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which pharmacological study is the first listed.
NCT00356980 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00356980 about?
NCT00356980 is a clinical study titled "TNF-Bound Colloidal Gold in Treating Patients With Advanced Solid Tumors". RATIONALE: Biological therapies, such as TNF-bound colloidal gold, may stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is studying the side effects and best dose of TNF-bound colloidal gold in treating patients with advanced solid tumors.
What is the current status of trial NCT00356980?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2006-05. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00356980?
The interventions under investigation include: pharmacological study (OTHER), colloidal gold-bound tumor necrosis factor (BIOLOGICAL).
Who is sponsoring clinical trial NCT00356980?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.